Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 5104, 2103 Cornell Road, Cleveland, OH 44106, USA.
Exp Mol Pathol. 2011 Dec;91(3):673-81. doi: 10.1016/j.yexmp.2011.06.012. Epub 2011 Jul 23.
Foreign body-type multinucleated giant cells (FBGC), formed by macrophage fusion, are a prominent cell type on implanted biomaterials, although the roles they play at these and other sites of chronic inflammation are not understood. Why lymphocytes are present in this scenario and the effects of fusing macrophages/FBGC on subsequent lymphocyte responses are also unclear. To address the physiological significance of FBGC in this regard, we employed our in vitro system of interleukin (IL)-4-induced human monocyte-derived macrophage fusion/FBGC formation. Initially, we pursued the identities of lymphocyte co-stimulatory molecules on fusing macrophages/FBGC. In addition, we further compared the FBGC phenotype to that currently associated with osteoclasts and dendritic cells using recognized markers. Immunoblotting of cell lysates and immunochemistry of macrophages/FBGC in situ, revealed that IL-4-induced macrophages/FBGC strongly express HLA-DR, CD98, B7-2 (CD86), and B7-H1 (PD-L1), but not B7-1 (CD80) or B7-H2 (B7RP-1). Furthermore, molecules currently recognized to be expressed on osteoclasts (calcitonin receptor, tartrate-resistant acid phosphatase, RANK) or dendritic cells (CD1a, CD40, CD83, CD95/fas) are undetectable. In contrast, fusing macrophages/FBGC strongly express the macrophage markers αX integrin (CD11c), CD68, and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), whereas CD14 is completely down-modulated with IL-4-induced macrophage fusion. These novel data demonstrate that IL-4-induction of macrophage multinucleation/FBGC formation features the acquisition of a CD14-negative phenotypic profile which is distinguishable from that of dendritic cells and osteoclasts, yet potentially exhibits multiple capacities for lymphocyte interactions with resultant lymphocyte down-modulation.
异物型多核巨细胞(FBGC)是由巨噬细胞融合形成的一种突出的细胞类型,存在于植入的生物材料中,但人们并不了解其在这些部位和其他慢性炎症部位的作用。为什么淋巴细胞存在于这种情况下,以及巨噬细胞/FBGC 融合对随后的淋巴细胞反应有什么影响,目前也不清楚。为了解 FBGC 在这方面的生理意义,我们采用了体外白细胞介素(IL)-4 诱导的人单核细胞衍生的巨噬细胞融合/FBGC 形成系统。最初,我们研究了融合巨噬细胞/FBGC 上淋巴细胞共刺激分子的特性。此外,我们还使用公认的标志物将 FBGC 表型与目前与破骨细胞和树突状细胞相关的表型进行了比较。细胞裂解物的免疫印迹和巨噬细胞/FBGC 的免疫组织化学原位分析表明,IL-4 诱导的巨噬细胞/FBGC 强烈表达 HLA-DR、CD98、B7-2(CD86)和 B7-H1(PD-L1),但不表达 B7-1(CD80)或 B7-H2(B7RP-1)。此外,目前认为表达在破骨细胞(降钙素受体、抗酒石酸酸性磷酸酶、RANK)或树突状细胞(CD1a、CD40、CD83、CD95/fas)上的分子无法检测到。相比之下,融合巨噬细胞/FBGC 强烈表达巨噬细胞标志物 αX 整合素(CD11c)、CD68 和树突状细胞特异性细胞间黏附分子-3 抓取非整合素(DC-SIGN),而 CD14 在 IL-4 诱导的巨噬细胞融合时完全下调。这些新数据表明,IL-4 诱导的巨噬细胞多核化/FBGC 形成的特征是获得 CD14 阴性表型,与树突状细胞和破骨细胞不同,但可能具有多种与淋巴细胞相互作用的能力,从而导致淋巴细胞下调。